Ask about this productRelated genes to: TRAF3IP3 antibody
- Gene:
- TRAF3IP3 NIH gene
- Name:
- TRAF3 interacting protein 3
- Previous symbol:
- -
- Synonyms:
- T3JAM
- Chromosome:
- 1q32.2
- Locus Type:
- gene with protein product
- Date approved:
- 2005-06-02
- Date modifiied:
- 2016-10-05
Related products to: TRAF3IP3 antibody
Related articles to: TRAF3IP3 antibody
- Interferon-based local therapy is an intervention for high-risk human papillomavirus (HR-HPV)-associated low-grade squamous intraepithelial lesions (LSIL) or lower-grade cervical abnormalities. This study sought to delineate the differences in clinical outcomes following interferon-based local drug treatment and elucidate the microenvironmental factors driving these disparities. - Source: PubMed
Publication date: 2026/03/10
Ji LingyunWu JingZhou YangPu XiaowenWang XiaoXu BowenJiao RuixianWu WenjuanZhang Wenhong - Phosphatase and tensin homolog (PTEN) is a critical regulator of cell proliferation, differentiation, and inflammatory balance. However, its downstream proteomic effects in periodontal ligament stem cells (PDLSCs) remain poorly understood. This study aimed to elucidate the proteomic alterations induced by PTEN inhibition and identify potential molecular pathways underlying periodontal regeneration. - Source: PubMed
Publication date: 2026/03/20
Phothichailert SuphalakNowwarote NunthawanKornsuthisopon ChatvadeeMurakami ShinyaSrithanyarat Supreda SuphanantachatOsathanon Thanaphum - Sepsis is a life-threatening condition characterized by immune dysregulation, yet the mechanisms underlying T cell dysfunction remain poorly understood. - Source: PubMed
Publication date: 2025/09/13
Li XiangChen ZhibinYao YandongChen MuhuHu Yingchun - - Source: PubMed
Publication date: 2025/09/06
- Diffuse glioma, the most prevalent and malignant intracranial tumor, presents a formidable challenge due to its immunosuppressive microenvironment, which complicates conventional therapeutic approaches. This study conducted a comprehensive prognostic meta-analysis involving 2,968 patients with diffuse glioma and established a comprehensive machine learning framework with nested resampling of 18 machine learning algorithms, and developed the Immune Glioma Survival Signature (IGLoS). This signature, comprising CCL19, ICOSLG, IL11, PTGES, TNFAIP3, and TRAF3IP3, has been demonstrated to predict survival outcomes across a range of cancers and to correlate with tumor progression at the level of multi-omics. It is noteworthy that the IGLoS score enables precise patient stratification for personalized cancer treatments and elucidates pivotal resistance mechanisms to immunotherapy. Furthermore, siRNA screening has underscored the critical role of TRAF3IP3 in modulating PDL1 expression and immune pathways, with implications on the ERK pathway and NFATC2 involvement. Through single-cell analysis of published and in-house datasets, TRAF3IP3 exhibited selective enrichment in NPC-like and MES-like tumor cells, and showed a dual functionality in mediating T-Cell Exhaustion. Targeting TRAF3IP3 emerges as a promising avenue to combat immunotherapy resistance, particularly in glioma, thus paving the way for precision medicine. - Source: PubMed
Publication date: 2025/07/26
Yang YanboWang FeiZhang YulianHuang RunZhang ChuanpengZhao LuDang HanhanTao XinyuLu YueLu DengfengZhang YunshengHe KunWeng JiancongChen ZhouqingWang ZhongYu Yanbing